Axsome Therapeutics, Inc. Forecast, price target & analysts
Axsome Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Axsome Therapeutics, Inc. Classifications & Recommendation:
Axsome Therapeutics, Inc. Price Target
| Target Price | $177.71 |
| Price | $109.92 |
| Potential |
61.68%
register free of charge
|
| Number of Estimates | 18 |
|
18 Analysts have issued a price target Axsome Therapeutics, Inc. 2026 .
The average Axsome Therapeutics, Inc. target price is $177.71.
This is
61.68%
register free of charge
$216.00
96.52%
register free of charge
$143.00
30.10%
register free of charge
|
|
| A rating was issued by 18 analysts: 18 Analysts recommend Axsome Therapeutics, Inc. to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Axsome Therapeutics, Inc. stock has an average upside potential 2026 of
61.68%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 385.69 | 617.15 |
| 42.53% | 60.01% | |
| EBITDA Margin | -63.39% | -15.54% |
| 2.58% | 75.48% | |
| Net Margin | -75.59% | -22.11% |
| 20.25% | 70.75% |
18 Analysts have issued a sales forecast Axsome Therapeutics, Inc. 2025 . The average Axsome Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Axsome Therapeutics, Inc. EBITDA forecast 2025. The average Axsome Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 Axsome Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Axsome Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -5.99 | -2.80 |
| 13.66% | 53.26% | |
| P/E | negative | |
| EV/Sales | 8.50 |
9 Analysts have issued a Axsome Therapeutics, Inc. forecast for earnings per share. The average Axsome Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Axsome Therapeutics, Inc....
Current Axsome Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| RBC Capital |
Locked
➜
Locked
|
Locked | Apr 29 2025 |
| Jefferies |
Locked
➜
Locked
|
Locked | Apr 07 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 03 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Apr 01 2025 |
| Mizuho |
Locked
➜
Locked
|
Locked | Mar 27 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 06 2025 |
| Baird |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
RBC Capital:
Locked
➜
Locked
|
Apr 29 2025 |
|
Locked
Jefferies:
Locked
➜
Locked
|
Apr 07 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 03 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Apr 01 2025 |
|
Locked
Mizuho:
Locked
➜
Locked
|
Mar 27 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 06 2025 |
|
Locked
Baird:
Locked
➜
Locked
|
Mar 03 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
